F. Rioux et al., RECOMBINANT HUMAN HEMOGLOBIN INHIBITS BOTH CONSTITUTIVE AND CYTOKINE-INDUCED NITRIC OXIDE-MEDIATED RELAXATION OF RABBIT ISOLATED AORTIC RINGS, Journal of cardiovascular pharmacology, 24(2), 1994, pp. 229-237
A genetically engineered recombinant human hemoglobin (rHb1.1) was rec
ently developed for use as a blood substitute (Nature 1992;356:258-60)
. Like other mammalian hemoglobin (Hb) molecules, it might bind and an
tagonize the actions of nitric oxide (NO). We used an isolated rabbit
aortic ring preparation to examine the ability of rHb1.1 to inhibit ac
etylcholine (ACh)- and interleukin-1 beta (IL-1 beta)-induced reductio
ns of vasoconstrictor responses to the alpha-adrenoceptor agonist phen
ylephrine (PE). rHb1.1 (0.04-4.4 mu M) rapidly and reversibly inhibite
d, in a concentration-dependent manner, both ACh- and IL-1 beta-induce
d decreases in PE contractile responses. These inhibitory effects of r
Hb1.1 were noncompetitive and were equipotent to those of purified, ce
ll-free human Hb (p.hHb). These two forms of soluble Hb were at least
10 times more potent than Hb in erythrocytes (red blood cells: RBC-Hb)
. Both N-G-nitro-L-arginine (10 mu M) a NO synthase inhibitor, and LY-
83583 (10 mu M), a guanylyl cyclase inhibitor, mimicked the effects of
rHb1.1. The inhibitory effects of rHb1.1 were not shared by either hu
man serum albumin (HSA 44 mu M), which combines with but does not deac
tivate NO, or cytochrome C (44 mu M), a heme-containing protein that d
oes not bind NO; neither were they reversed by L-arginine (L-ARG) (1 m
M), the presumed NO precursor. These and other results suggest that th
e chemical antagonism of NO is likely to be the mechanism by which rHb
1.1 and other Hbs inhibit ACh- and IL-1 beta-induced decreases in the
response to PE in rabbit aortic rings.-